Side-by-side comparison of AI visibility scores, market position, and capabilities
Patient scheduling and engagement platform for multi-specialty practices, combining intelligent scheduling, reminders, and digital intake. Franklin TN, raised $41M+.
Relatient is a patient engagement and scheduling company that provides healthcare providers with an integrated platform for scheduling automation, appointment reminders, digital check-in, and patient communication. Founded in 2013 and headquartered in Franklin, Tennessee, Relatient has raised more than $41 million and serves health systems, hospital outpatient departments, and multi-specialty physician groups across the United States. The company's Dash platform delivers intelligent self-scheduling, automated reminder workflows, digital intake forms, and post-visit survey capabilities through a single system that integrates with major EHR and practice management software.\n\nRelatiently's Dash scheduling platform is built around intelligent appointment matching, directing patients to the right provider, location, and appointment type based on clinical criteria and insurance requirements rather than offering a simple open calendar view. This smart scheduling approach reduces scheduling errors and the downstream revenue cycle problems they cause, while improving the patient experience by eliminating the friction of calling and navigating phone trees. The platform supports scheduling across complex multi-provider, multi-location organizations where routing rules are an important operational requirement.\n\nRelatiently competes in a market that has grown significantly as providers recognize the revenue and operational impact of patient access optimization. The company differentiates through its depth of EHR integration, its focus on enterprise multi-specialty environments, and its comprehensive approach to the full patient engagement lifecycle from first contact through post-visit follow-up. Relatient's combination of scheduling intelligence and communication automation serves as an integrated patient access solution for organizations that need more than basic reminder tools.
Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.
Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.